

iShares NASDAQ US Biotechnology UCITS ETF USD (Acc)

Key Information

Name	iShares NASDAQ US Biotechnology UCITS ETF USD (Acc)
Provider	iShares
Trading Currency	USD
Fund Currency	USD
Operating MIC	XLON
Index Name	Nasdaq Biotechnology
ETP Type	ETF
UCITS eligible	Yes
Inception Date	2017-10-23
Last NAV (per 2022-01-11)	USD 7.83


Net asset value - YTD

since 01.01.2022



Net asset value

since 2018-09-12



Identifier

ISIN	IE00BYXG2H39
Valor	37978279
WKN	A2DWAU
Bloomberg Ticker	BTEC LN

Asset Structure

Asset Class Top Level	Equity
Asset Class Mid Level	Small Cap
Region	North America

Configuration

Use of Income	Accumulation
Replication Methodology	Physical

Administration

Issuing Company	iShares IV plc
Administrator	State Street Fund Services (Ireland) Limited
Custodian	State Street Custodial Services (Ireland) Limited

The information contained in this report is for demo and testing purposes only. The information is provided by inETF and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the report or the information, products, services, or related graphics contained on the report for any purpose. Any reliance you place on such information is therefore strictly at your own risk. In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this report. Through this report you are able to link to other reports which are not under the control of inETF. We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them. Every effort is made to keep the report up and running smoothly. However, inETF takes no responsibility for, and will not be liable for, the report being temporarily unavailable due to technical issues beyond our control.